Pyridostigmine bromide

  • Mestinon
  • 3-(Dimethylcarbamyloxy)-1-methylpyridinium bromide
  • 3-Hydroxy-1-methylpyridinium bromide dimethylcarbamate
  • Kalymin
Formula
C9H13BrN2O2
Structure
Description
White or practically white, crystalline powder. Agreeable odor.
Uses
Medication.

Registry Numbers and Inventories.
CAS
101-26-8
EC (EINECS/ELINCS)
202-929-9
RTECS
UU5270000
RTECS class
Drug; Reproductive Effector; Human Data
Merck
12,8161
Beilstein/Gmelin
3764573
Beilstein Reference
4-21-00-00415
Japan ENCS (MITI)
Listed
Korea ECL
Listed

Properties.
Formula
C9H13N2O2*Br
Formula mass
261.12
Melting point, °C
154 - 155
Solubility in water
Freely soluble

Hazards and Protection.
Storage
Keep in a cool, dry location in a tightly closed container when not in use.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Plastic/rubber gloves, safety goggles and disposable coveralls.
Respirators
Half face, negative pressure air purifying, dust/mist/fume efficiency filter respirator. Supplied air, full facepiece respirator.
Small spills/leaks
Scoop/shovel material into a suitably labeled drum. Secure drum cover and move container to a safe holding area.
Stability
Stable at normal temperatures and pressures in in a tightly sealed container.
Decomposition
Oxides of carbon, oxides of nitrogen, hydrogen bromide and brominated compounds.

Fire.
Fire fighting
Extinguish with water, carbon dioxide, dry chemical or foam. Wear NIOSH/MSHA approved, positive pressure SCBA and full protective turn out gear.

Health.
Exposure effects
Abnormally low blood pressure may occur from peripheral actions. However, elevated blood pressure may also be seen secondary to the anxiety resulting from the effects on other organ systems. Likewise, bradyarrhythmias are common from the antimyasthenics, but rapid heart rate may occur secondary to the anxiety resulting from the effects on other organ systems. Respiratory rate may be increased in patients with airway compromise. seizures and coma have been described; profound weakness and muscle fasciculations may also occur. In less severe cases, headache, dizziness, and dysarthria may occur. Parkinsonian-like symptoms have been reported during therapeutic use of pyridostigmine.
   Ingestion
Cramping, abdominal pain, hyperperistalsis, vomiting, and diarrhea have been described.
   Inhalation
Excess secretions in the tracheal tree, bronchospasm, and pulmonary edema may occur.
   Skin
Dermatitis, urticaria and reversible alopecia have been reported.
   Eyes
Constriction of the pupil, blurred vision, and excessive secretions in the nose and throat may be present.

First aid
 
   Ingestion
Never induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person. Obtain medical assistance.
   Inhalation
Remove to fresh air. Give CPR, oxygen if needed.
   Skin
Immediately wash with soap and water.
   Eyes
Flush with water for 15 minutes.

Transport.